![A New Approach to Treat Childhood Leukemia: Novartis' CAR-T Therapy - Frazer A. Tessema, Jonathan J. Darrow, 2017 A New Approach to Treat Childhood Leukemia: Novartis' CAR-T Therapy - Frazer A. Tessema, Jonathan J. Darrow, 2017](https://journals.sagepub.com/cms/10.1177/1073110517750609/asset/images/large/10.1177_1073110517750609-fig2.jpeg)
A New Approach to Treat Childhood Leukemia: Novartis' CAR-T Therapy - Frazer A. Tessema, Jonathan J. Darrow, 2017
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
![Frontiers | Chimeric Antigen Receptor, Teamwork, Education, Assessment, and Management (CAR-TEAM): A Simulation-Based Inter-professional Education (IPE) Intervention for Management of CAR Toxicities Frontiers | Chimeric Antigen Receptor, Teamwork, Education, Assessment, and Management (CAR-TEAM): A Simulation-Based Inter-professional Education (IPE) Intervention for Management of CAR Toxicities](https://www.frontiersin.org/files/Articles/555516/fonc-10-01227-HTML/image_m/fonc-10-01227-g001.jpg)
Frontiers | Chimeric Antigen Receptor, Teamwork, Education, Assessment, and Management (CAR-TEAM): A Simulation-Based Inter-professional Education (IPE) Intervention for Management of CAR Toxicities
![FDA Advisory Committee Recommends Approval of CAR-T Cell Therapy and Two New Biosimilars | Biosimilars Law Bulletin FDA Advisory Committee Recommends Approval of CAR-T Cell Therapy and Two New Biosimilars | Biosimilars Law Bulletin](https://www.biosimilarsip.com/wp-content/uploads/sites/768/2017/03/Flask-Perodic-Table-Structures.jpg)
FDA Advisory Committee Recommends Approval of CAR-T Cell Therapy and Two New Biosimilars | Biosimilars Law Bulletin
![Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell | Nature Medicine Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-018-0201-9/MediaObjects/41591_2018_201_Fig1_HTML.png)
Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell | Nature Medicine
![Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas | Nature Medicine Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas | Nature Medicine](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41591-020-1061-7/MediaObjects/41591_2020_1061_Fig1_HTML.png)
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas | Nature Medicine
![Mesoblast faces FDA pushback over cell therapy manufacturing, clinical data: documents | Fierce Pharma Mesoblast faces FDA pushback over cell therapy manufacturing, clinical data: documents | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1597239104/GettyImages-1141713510.jpg/GettyImages-1141713510.jpg?VersionId=2TulzrgHkUcCbELeWNrWk.khPeq6IxoC)
Mesoblast faces FDA pushback over cell therapy manufacturing, clinical data: documents | Fierce Pharma
![Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma | Nature Communications Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-020-17175-8/MediaObjects/41467_2020_17175_Fig1_HTML.png)
Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma | Nature Communications
FDA Advisory Committee Recommends Approval of CAR-T Cell Therapy and Two New Biosimilars | Biosimilars Law Bulletin
![With 2-pronged filing, Novartis' CAR-T med Kymriah aims to jump into Europe with both feet | Fierce Pharma With 2-pronged filing, Novartis' CAR-T med Kymriah aims to jump into Europe with both feet | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/FiercePharma-1509992015/novartis-hq.jpg?VersionId=YYMzPp.e6z20yPvG7J1ghKjtC8xgW5BF)
With 2-pronged filing, Novartis' CAR-T med Kymriah aims to jump into Europe with both feet | Fierce Pharma
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
![Current state of U.S. Food and Drug Administration regulation for cellular and gene therapy products: potential cures on the horizon - Cytotherapy Current state of U.S. Food and Drug Administration regulation for cellular and gene therapy products: potential cures on the horizon - Cytotherapy](https://www.isct-cytotherapy.org/cms/attachment/c08cbfdb-5a02-4ac4-8a9f-3c6df3d9cc6b/gr1_lrg.jpg)
Current state of U.S. Food and Drug Administration regulation for cellular and gene therapy products: potential cures on the horizon - Cytotherapy
![Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results | Nature Medicine Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-022-02182-7/MediaObjects/41591_2022_2182_Fig1_HTML.png)
Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results | Nature Medicine
![Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy | Nature Reviews Clinical Oncology Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy | Nature Reviews Clinical Oncology](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41571-018-0075-2/MediaObjects/41571_2018_75_Fig1_HTML.png)
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy | Nature Reviews Clinical Oncology
![A New Approach to Treat Childhood Leukemia: Novartis' CAR-T Therapy - Frazer A. Tessema, Jonathan J. Darrow, 2017 A New Approach to Treat Childhood Leukemia: Novartis' CAR-T Therapy - Frazer A. Tessema, Jonathan J. Darrow, 2017](https://journals.sagepub.com/cms/10.1177/1073110517750609/asset/images/large/10.1177_1073110517750609-fig1.jpeg)